Alexza appoints J. Kevin Buchi to board of directors

Alexza Pharmaceuticals has announced the appointment of J. Kevin Buchi to its board of directors. Buchi, who was Corporate Vice President, Global Branded Products at Teva Pharmaceutical Industries from October 2011 until May 2012, has over 30 years of experience in the pharmaceutical industry.

Alexza’s Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic and bi-polar patients was approved by the FDA in December 2012.

Company President and CEO Thomas B. King commented, “We are very pleased to welcome Kevin to our Board of Directors. This will be a transitional year for us, as we move from a development-stage company to a commercial company with the launch of Adasuve. Kevin brings a wealth of experience and expertise to our Board, particularly in product commercialization, partnering and overall corporate development. We look forward to his contributions to Alexza’s next phase.”

Read the Alexza press release.

Share

published on

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan

September 15-September 18DDL New Researcher Network Summer Event, London, UK

September 16-September 17IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA